Prediction Case File
YouTubeEvaluation Complete

DISCLAIMER

2 extracted signals · 2 resolved · 0 still active

EFMS TRADE profile imageEFMS TRADEIndependent analyst profile
Source published
08 Sept 2025, 05:16 UTC
Recorded by Tahlil Plus
18 May 2026, 20:23 UTC
Video preview for DISCLAIMER
Source overview

AI-generated source summary

Gold turning point at 3591.6. If the price goes below 3589.79, selling is expected targeting 3540 or 3535. Above 3591, expect a target of 3605, possibly extending to 3638 or 3646. DXY is expected to retest bearish move. If DXY rejection then bearish to Gold bullish. BTC is showing range with demand around 109800 immediate support.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Evaluation Complete
Signals
2
Extracted from this source
Open
0
Still being tracked
Successful
2
Resolved successfully
Failed
0
Resolved unsuccessfully
Other
0
Cancelled, invalid or excluded
Resolved success
100%
2 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  3. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

  4. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  5. Market predictions extracted

    2 eligible signals linked to this case.

  6. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

Analyst snapshot

EFMS TRADE

Platform-wide history, separate from this source evaluation.

Reliability
64.1
Tracked signals
337
Historical success
57.8%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail